ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Account Active
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / ELVN / financials
DYN (26) IDYA (34) TLX (47) BHC (68) ⌘ Pro Terminal β†’

Enliven Therapeutics Inc. (ELVN) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$44.63 +0.86% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $44.61

Enliven Therapeutics Inc. (ELVN) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $3.24B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ELVN Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is ELVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Enliven Therapeutics Inc. (NASDAQ: ELVN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $44.63 (+0.86% 1D, market cap $3.24B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ELVN ranks #481 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does ELVN compare to DYN and IDYA in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELVN carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -26.2%. By comparison, DYN (Dyne Therapeutics Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $3.12B) and IDYA (IDEAYA Biosciences Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -13.8%, cap $3.08B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ELVN?
β–Ό

Per ELVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001672619), Enliven Therapeutics Inc. generated $335.0M in revenue (+14.4% YoY), -$103.7M in net income, and -$70.3M in free cash flow against $476.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $44.61 (-0.04%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 7/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (39/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510039
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk D
Cash (7)Whales (9)SEC (10)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-8.6% Base Target
$65 Bull$41 Base$32 Bear
πŸ“¬ FREE ELVN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for ELVN)Realized 20D OHLCV Swing Band: Β±8.4%
Deterministic 5-Pillar Attribution (39/100 Composite)
πŸ” WHY ELVN SCORES 39/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 2/9

β–² #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)

FRED Regime Γ— Technicals: 63% of 52W Range β€’ RSI-14 at 50.7 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
31
Grade E$39.49+4.5% Next Q
Q2 (-2Q)
34
Grade E$41.25+5.9% Next Q
Q3 (-1Q)
36
Grade E$43.69+2.2% Next Q
Current
39
Grade D-$44.63-7.6% Hist 90D Ξ±
Trajectory: E (31) β†’ D- (39)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a ELVN Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While ELVN currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($48.07) and Max Pain ($46.86) forces dealer call-delta covering toward $65.44.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ELVNβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œELVN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 39%NO 61%Trade / Inspect Odds β†’
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL β€’ FY 2025 (10-K)

How ELVN Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$335.0MGross Profit $174.2M (52%)Cost of Sales $160.8MOp Profit $0 (0%)OpEx (R&D/SG&A) $174.2MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

β–  Revenueβ–  Net Profitβ–  Free Cash Flow
FY23
Rev $233.9M
FY24
Rev $292.8M
FY25
Rev $335.0M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$335.0M52%-35.7%-$103.7M-$70.3M-26.2%
FY 2024$292.8M52%-35.7%-$89.0M-$73.2M-44.5%
FY 2023$233.9M52%-35.7%-$71.6M-$61.3M-26.2%
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ELVN)

  • βœ“Walkthrough of ELVN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
ELVN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +7.26%β–² ASCENDING CHANNEL
2026-11-03O $45.08H $45.08L $44.25C $44.63VOL 1.24M
RES: $73.64SUP: $37.42SMA50: $48.07SMA200: $42.92
$64.93$54.11$43.28$32.45$21.62RES $73.64SUP $37.42$44.632026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ELVN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ ELVN Butterfly Map β†’ + Track ELVN β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +14.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ELVN today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for ELVN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ELVN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ELVN)

Health Care Rank #481 of 1015 βš”οΈ DYN vs ELVN Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (ELVN vs. DYN, IDYA, TLX, BHC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Enliven Therapeutics Inc. (ELVN) ranks #481 by composite RQD confidence (39/100, grade D-) and #197 by equity capitalization ($3.24B). Within this direct 5-issuer industry benchmark cohort, BHC leads on earnings valuation at 21.2x trailing P/E, while BHC leads on capital efficiency and profitability with 7.6% ROIC and β€” gross margin. BHC currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with ELVN at 39/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ELVN ACTIVE
Enliven Therapeutics Inc.
D- 39/100 β€” β€” -26.2% +0.86% $3.24B Benchmark Subject
DYN
Dyne Therapeutics Inc.
E 26/100 β€” β€” -35.0% +3.66% $3.12B /dyn-vs-elvn β†’
IDYA
IDEAYA Biosciences Inc.
E 34/100 β€” β€” -13.8% -1.00% $3.08B /idya-vs-elvn β†’
TLX
Telix Pharmaceuticals Limited
D 47/100 β€” β€” β€” -0.55% $3.08B /tlx-vs-elvn β†’
BHC
Bausch Health Companies Inc.
C+ 68/100 21.2x β€” 7.6% -2.19% $3.07B /bhc-vs-elvn β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001672619 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Enliven Therapeutics Inc. (ELVN) reported GAAP revenue of $335.0M (+14.4% vs. FY2024 revenue of $292.8M , and +43.3% cumulative change since FY2023) , GAAP net income of -$103.7M, operating cash flow of -$70.3M, and free cash flow of -$70.3M (+3.9% YoY). On the balance sheet, ELVN closed FY2025 with $476.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $335.0M -$103.7M -$70.3M -$70.3M $476.2M β€”
FY2024 (FY) 2024-12-31 $292.8M -$89.0M -$73.2M -$73.2M $325.8M β€”
FY2023 (FY) 2023-12-31 $233.9M -$71.6M -$61.3M -$61.3M β€” β€”

3. ELVN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ELVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Enliven Therapeutics Inc. (NASDAQ: ELVN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $44.63 (+0.86% 1D, market cap $3.24B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ELVN ranks #481 in composite RQD confidence.

How does ELVN compare to DYN and IDYA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELVN carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -26.2%. By comparison, DYN (Dyne Therapeutics Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $3.12B) and IDYA (IDEAYA Biosciences Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -13.8%, cap $3.08B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ELVN?

Per ELVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001672619), Enliven Therapeutics Inc. generated $335.0M in revenue (+14.4% YoY), -$103.7M in net income, and -$70.3M in free cash flow against $476.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ELVN trading relative to its 50-day, 200-day, and 52-week technical levels?

ELVN last traded at $44.63 (+0.86% on volume of 1,138,673 shares), positioning the stock -7.16% below its 50-day simple moving average ($48.07) and +3.98% above its 200-day simple moving average ($42.92). Across its 52-week range of $14.78 to $62.32, ELVN sits at the 62.8% percentile with a 14-day RSI of 50.7 (NEUTRAL RANGE) and an implied next-earnings move of Β±8.4% ($40.88 to $48.38).

Direct Sub-Reports: ELVN RQD Cockpit ELVN 12M Forecast ELVN Earnings & Move ELVN Dividends & DRIP ELVN Insiders & 13F ELVN Whale Options ELVN Profit Sankey ELVN News & Why
ROARABLE RATING BRIEF β€’ RQD 39/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

ELVN β€” Enliven Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Enliven Therapeutics Inc. (ELVN) earns a live Roarable RQD composite score of 39/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $44.63 (+0.86% 1D, market capitalization $3.24B).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -26.2%, gross margin of β€”, operating margin of β€”, and free cash flow yield of -2.13%.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Enliven Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The company carries a market capitalization of $3.3B. Per the news section, its lead program referenced is relacobatinib (ELVN-001) for previously treated chronic myeloid leukemia, with a Phase 3 trial design (ENABLE-2) reported as aligned with the FDA. The FY 2025 and FY 2024 financials report β€” revenue, indicating no reported revenue in those periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Enliven Therapeutics Inc. (ELVN) reported $335.0M in annual revenue (up from $292.8M in FY2024, +14.4% YoY) and -$103.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($233.9M revenue, -$71.6M net income) through FY2025, ELVN scaled operating cash flow to -$70.3M and free cash flow to -$70.3M, backed by $476.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 39/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -2.13% and institutional whale pillar of 9/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $14.78 – $62.32 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies cannot be mapped from the source data. β€” for sector correlation coefficients.

  • Key Question #1: Can ELVN sustain or expand its β€” operating margin and -26.2% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $335.0M and free cash flow of -$70.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ELVN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ELVN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Enliven Therapeutics Inc. (ELVN) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to ELVN Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ELVN Bull vs. Bear Conversation Board β€” What's Your Call at $44.63?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ELVN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ELVN:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER β€’ Growth & Tech Investor πŸ‚ BULLISH 🎯 Target: $56.20 (+27.0%)
πŸ“Œ Pinned Debate

FDA alignment on the ENABLE-2 Phase 3 design for relacobatinib in previously treated CML is the sharpest near-term catalyst in the feed

FDA alignment on the ENABLE-2 Phase 3 design for relacobatinib in previously treated CML is the sharpest near-term catalyst in the feed.. When you look under the hood at ELVN, Fundamental Cash Engine is 7/20 with 0.0% gross margins and -26.2% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (9/20) has been quietly accumulating below $62.32. My 12M target is $56.20.

RetailWhale_TX πŸ‚ BULL

@FadeTheHype Shorting a 9/20 institutional whale-flow stock at $44.25 is dangerous when funds are rotating into Health Care.

FA FadeTheHype RQD DEBATE OPENER β€’ Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $37.17 (-16.0%)
Spot @ $44.25

A -26.2% ROIC, -2.13% FCF yield, and a 3 / 20 insider conviction score point to a cash engine that is burning capital with weak insider

Here is the bear case nobody on the bull side wants to address on ELVN: A -26.2% ROIC, -2.13% FCF yield, and a 3 / 20 insider conviction score point to a cash engine that is burning capital with weak insider backing.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE